Brinks DEA Consulting Welcomes Daniel Dormont, One of the Nation’s Leading Controlled Substances Experts
Is the DEA’s non-retrievable standard too much? Maybe it’s time to change the non-retrievable standard?
Exciting Change in DEA Statutes: Pharmacy Delivery of Controlled Substances to Practitioners Expands Beyond MOUD
Case Study Hospitals Under Fire: Poor Prescribing Oversight Leads to Expensive Settlements, Is Your Hospital Monitoring the Prescriptions Written by Your Practitioners?
Why Congress Must Fix 21 U.S.C. 829a(a): The Hidden Impact of the SUPPORT Act on Patient Care. Do you know the serious issues this law created—and how they could be limiting access to treatment?
